Related coverage linked through entity extraction aliases.
Aug 03, 2026
FDA approved a subcutaneous starting dose of Leqembi for early Alzheimer's disease. AAIC 2026 real-world data showed most patients stable or improved; a mouse study found KCL-286 repaired DNA damage and reduced inflammation.
Jul 23, 2026
A Cochrane review finds exercise for hip osteoarthritis reduces pain by 7 points on a 100-point scale, below the 12-point threshold for noticeable benefit. A survey shows 76% of physical therapy patients skip home exercises, citing forgetfulness and time constraints. A study reports only 22% of stroke and brain injury survivors receive intensive inpatient rehab, with disparities by race, insurance, and income.
May 14, 2026
The FDA cleared neuromodulation devices from Epineuron, Aneuvo and Encora Therapeutics. The products address peripheral nerve surgery, spinal cord injury neurorehabilitation and essential tremor.
Apr 24, 2026
A preclinical study in Precision Clinical Medicine found that luteolin and astragaloside IV improved recovery after severe spinal cord injury in cell and rat models. The combined treatment reduced oxidative stress and neuroinflammation and improved motor function over five weeks.
Apr 09, 2026
AbbVie updated its completed Phase 2 elezanumab study in acute traumatic cervical spinal cord injury. The placebo-controlled trial began in March 2020 and its latest public update was posted on February 9, 2026.
Feb 13, 2026
Scientists at Northwestern University developed human spinal cord organoids that accurately replicate injury responses including cell death, inflammation, and glial scarring. Testing showed a "dancing molecules" therapy significantly reduced scarring and promoted nerve regrowth.
